A Study for Patients With Rheumatoid Arthritis on Methotrexate (MTX) With an Inadequate Response to TNFα Inhibitor Therapy
Status:
Completed
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to explore whether LY2127399 is effective in relieving signs and
symptoms of rheumatoid arthritis (RA) in patients with a history of inadequate response or
intolerance to at least 1 Tumor Necrosis Factor-Alpha (TNFα) inhibitor therapy. Examples of
these TNFα inhibitor therapies that are currently on the market include Enbrel® (etanercept),
Remicade® (infliximab), and Humira® (adalimumab).